According to a Public Citizen report (here), stronger enforcement is needed to deter pharmaceutical manufacturers from continuing to break the law and defraud federal and state health programs. The report – an update to a previous study released in 2012 with additional data through 2015 – catalogues all major financial settlements and court judgments between pharmaceutical companies and federal and state governments from 1991 through 2015, which totaled $35.7 billion.
Of the 373 settlements over those 25 years, 140 were federal settlements totaling $31.9 billion, and 233 were state settlements totaling $3.8 billion. GlaxoSmithKline and Pfizer reached the most settlements and paid the most in financial penalties – $7.9 billion and $3.9 billion, respectively. From 1991 through 2015, 31 companies entered into repeat settlements with the federal government. The violation resulting in the most federal penalties was unlawful promotion, usually off-label marketing.
There is one surprising result.
Read more »
Of the 373 settlements over those 25 years, 140 were federal settlements totaling $31.9 billion, and 233 were state settlements totaling $3.8 billion. GlaxoSmithKline and Pfizer reached the most settlements and paid the most in financial penalties – $7.9 billion and $3.9 billion, respectively. From 1991 through 2015, 31 companies entered into repeat settlements with the federal government. The violation resulting in the most federal penalties was unlawful promotion, usually off-label marketing.
 |
| Click on image for an enlarged view |
Read more »
25 Years of Pharma Criminal and Civil Penalties: Off-Label Marketing Tops the List, But...
Reviewed by admin
on
March 31, 2016
Rating:
Reviewed by admin
on
March 31, 2016
Rating:
No comments: